These findings underscore the potential of ALKBH5 and FTO expression as a biomarker in JIA and identify the m6A machinery as a potential therapeutic target for the treatment of JIA and possibly other autoimmune diseases in the future. This evidence concerns the gene FTO and autoimmune disease.